MCID: PLS016
MIFTS: 43

Plasma Cell Leukemia

Categories: Rare diseases, Cancer diseases, Blood diseases

Aliases & Classifications for Plasma Cell Leukemia

MalaCards integrated aliases for Plasma Cell Leukemia:

Name: Plasma Cell Leukemia 49 55 51
Leukemia, Plasma Cell 49 69
Pcl 55

Characteristics:

Orphanet epidemiological data:

55
plasma cell leukemia
Inheritance: Not applicable; Prevalence: <1/1000000 (Europe); Age of onset: Adult,Elderly; Age of death: adult,elderly;

Classifications:



External Ids:

Orphanet 55 ORPHA454714
UMLS via Orphanet 70 C0023484
ICD10 via Orphanet 33 C90.1
ICD10 32 C90.1

Summaries for Plasma Cell Leukemia

NIH Rare Diseases : 49 Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma that involves high levels of plasma cells circulating in the peripheral blood. The signs and symptoms of PCL include aggressive clinical features, such as extramedullary disease, bone marrow failure, advanced stage disease and expression of distinct immunophenotypic markers. Different types of treatments are available for patients with PCL. Some treatments are standard (the currently used treatment), and some are being tested in clinical trials. For detailed information on the available treatment options, please visit the following link. http://www.cancer.gov/cancertopics/pdq/treatment/myeloma/Patient/page4 Last updated: 2/20/2014

MalaCards based summary : Plasma Cell Leukemia, also known as leukemia, plasma cell, is related to myeloma, multiple and lymphedema, hereditary, ia. An important gene associated with Plasma Cell Leukemia is CCND1 (Cyclin D1), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Interleukin-4 and 13 signaling. The drugs Dexamethasone and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and testes, and related phenotype is vision/eye.

Wikipedia : 72 Plasma cell leukemia (PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant... more...

Related Diseases for Plasma Cell Leukemia

Diseases related to Plasma Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Related Disease Score Top Affiliating Genes
1 myeloma, multiple 29.9 CCND1 FGFR3 IRF4 MAF NCAM1
2 lymphedema, hereditary, ia 11.2
3 plasmacytic leukemia 11.1
4 leukemia 10.9
5 plasmacytoma 10.1
6 lymphoma 10.1
7 chondromyxoid fibroma 10.0 CCND1 FGFR3
8 ring chromosome y syndrome 10.0
9 bladder urothelial carcinoma 9.9 CCND1 FGFR3
10 marginal zone b-cell lymphoma 9.9 CCND1 IRF4
11 personality disorder 9.9
12 lymphoma, mucosa-associated lymphoid type 9.9 CCND1 IRF4
13 diffuse large b-cell lymphoma 9.8 CCND1 IRF4
14 angioimmunoblastic t-cell lymphoma 9.8
15 follicular lymphoma 9.8 CCND1 IRF4
16 papilloma 9.8 CCND1 FGFR3
17 epithelial predominant wilms' tumor 9.8 MAF NCAM1
18 colorectal cancer 9.8
19 lung cancer 9.8
20 gastric cancer 9.8
21 bile duct carcinoma 9.8 CCND1 NCAM1
22 nephrogenic adenofibroma 9.8 MAF NCAM1
23 human herpesvirus 8 9.7
24 b-cell expansion with nfkb and t-cell anergy 9.7
25 macroglobulinemia 9.7
26 blood group, i system 9.7
27 amyloidosis 9.7
28 meningitis 9.7
29 endosteal hyperostosis, autosomal dominant 9.7
30 hematopoietic stem cell transplantation 9.7
31 myelofibrosis 9.7
32 peripheral t-cell lymphoma 9.7
33 hepatitis c 9.6
34 thyroiditis 9.6
35 episodic pain syndrome, familial, 1 9.6
36 cholecystitis 9.6
37 measles 9.6
38 acalculous cholecystitis 9.6
39 myeloid leukemia 9.6
40 leukemia, chronic lymphocytic 2 9.6
41 pulmonary hypertension 9.6
42 hairy cell leukemia 9.6
43 adult t-cell leukemia 9.6
44 glucosephosphate dehydrogenase deficiency 9.6
45 crohn's disease 9.6
46 cystadenocarcinoma 9.6
47 dengue disease 9.6
48 serous cystadenocarcinoma 9.6
49 leukemia, chronic lymphocytic 9.6
50 extramedullary plasmacytoma 9.6

Graphical network of the top 20 diseases related to Plasma Cell Leukemia:



Diseases related to Plasma Cell Leukemia

Symptoms & Phenotypes for Plasma Cell Leukemia

MGI Mouse Phenotypes related to Plasma Cell Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 vision/eye MP:0005391 8.92 CCND1 FGFR3 MAF NCAM1

Drugs & Therapeutics for Plasma Cell Leukemia

Drugs for Plasma Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 121)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
3
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
4
Melphalan Approved Phase 2,Phase 1 148-82-3 460612 4053
5
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Lenograstim Approved, Investigational Phase 1, Phase 2 135968-09-1
7
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
8
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
9
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
10
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
11
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
12
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
13
Acetaminophen Approved Phase 2 103-90-2 1983
14
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
15
Allopurinol Approved Phase 2 315-30-0 2094
16
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
17
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
18
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
19
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
20
Everolimus Approved Phase 2 159351-69-6 6442177
21
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
22
Promethazine Approved, Investigational Phase 2 60-87-7 4927
23
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
24
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
25
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
26 Pomalidomide Approved Phase 2 19171-19-8
27 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
28
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 21704 32326
29
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
30
Daratumumab Approved Phase 2 945721-28-8
31
Asparaginase Approved, Investigational Phase 2 9015-68-3
32
Pegaspargase Approved, Investigational Phase 2 130167-69-0
33
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 77-92-9 311
34 tannic acid Approved, Nutraceutical Phase 2
35
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
36
Doxil Approved June 1999 Phase 2 31703
37 Dexamethasone acetate Phase 2,Phase 1 1177-87-3
38 interferons Phase 2
39 glucocorticoids Phase 2,Phase 1
40
protease inhibitors Phase 2,Phase 1
41 Gastrointestinal Agents Phase 2,Phase 1
42 Topoisomerase Inhibitors Phase 2,Phase 1
43 HIV Protease Inhibitors Phase 2,Phase 1
44 Hormone Antagonists Phase 2,Phase 1
45 Hormones Phase 2,Phase 1
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2,Phase 1
47 Peripheral Nervous System Agents Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 2,Phase 1
49 Antiemetics Phase 2,Phase 1
50 Immunoglobulin A Phase 2

Interventional clinical trials:

(show all 28)

# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Unknown status NCT01435720 Phase 1, Phase 2
3 Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
4 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Completed NCT02858999 Phase 2 PAD-VCD
5 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
7 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
8 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
9 Allo HSCT Using RIC for Hematological Diseases Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
10 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
11 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
12 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
13 MUK Nine b: OPTIMUM Treatment Protocol Not yet recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
14 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Not yet recruiting NCT03314974 Phase 2
15 Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
16 Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma Terminated NCT01658904 Phase 1, Phase 2 Carfilzomib;Melphalan;Filgrastim
17 Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
18 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
19 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
20 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
21 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
22 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
23 Study of Arry-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma Active, not recruiting NCT01372540 Phase 1 Arry-520;Carfilzomib;Dexamethasone;Filgrastim
24 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Active, not recruiting NCT00988013 Phase 1
25 MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Suspended NCT03031730 Phase 1 Carfilzomib;Dexamethasone;Lenalidomide;MDM2 Inhibitor AMG-232
26 Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
27 High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT03389347
28 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Recruiting NCT01962636 Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil

Search NIH Clinical Center for Plasma Cell Leukemia

Genetic Tests for Plasma Cell Leukemia

Anatomical Context for Plasma Cell Leukemia

MalaCards organs/tissues related to Plasma Cell Leukemia:

38
Bone Marrow, Bone, Testes, T Cells, B Cells, Kidney, Skin

Publications for Plasma Cell Leukemia

Articles related to Plasma Cell Leukemia:

(show top 50) (show all 387)
# Title Authors Year
1
Lymphoplasmacytoid cytology in plasma cell leukemia. ( 29027254 )
2018
2
Sequential development of monoclonal B cell lymphocytosis-derived small lymphocytic lymphoma and plasma cell leukemia. ( 29417202 )
2018
3
Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14). ( 29064593 )
2018
4
Plasma Cell Leukemia Masquerading as a Relapse of the Nephrotic Syndrome. ( 29401321 )
2018
5
The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). ( 29108331 )
2017
6
Plasma cell leukemia with t(11;14)(q13;q32) simulating lymphoplasmacytic lymphoma - a diagnostic challenge solved by flow cytometry. ( 28270351 )
2017
7
Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition. ( 28255016 )
2017
8
A case of primary plasma cell leukemia exhibiting hemophagocytic plasma cells relapsed with multiple cutaneous plasmacytoma. ( 29333413 )
2017
9
Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. ( 28544116 )
2017
10
Acute Renal failure caused by plasma cell infiltration in primary plasma cell leukemia. ( 28792128 )
2017
11
Leukemia Cutis Associated with Secondary Plasma Cell Leukemia. ( 28620566 )
2017
12
Successful Intrathecal Chemotherapy Combined with Radiotherapy Followed by Pomalidomide and Low-Dose Dexamethasone Maintenance Therapy for a Primary Plasma Cell Leukemia Patient. ( 28286633 )
2017
13
Progression of cutaneous plasmacytoma to plasma cell leukemia in a dog. ( 28186653 )
2017
14
Flaming plasma cell leukemia. ( 28120778 )
2017
15
Morphological Transformation of Myeloma Cells into Multilobated Plasma Cell Nuclei within 7 Days in a Case of Secondary Plasma Cell Leukemia That Finally Transformed as Anaplastic Myeloma. ( 29430310 )
2017
16
Plasma Cell Leukemia Presenting with Hyperleukocytosis and Anaplasia. ( 28194071 )
2017
17
Plasmacytomas and Plasma-Cell Leukemia. ( 28296609 )
2017
18
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. ( 29066491 )
2017
19
Histone deacetylase inhibitors in plasma cell leukemia treatment: Effect of bone marrow microenvironment. ( 28043150 )
2017
20
Rapid Fatal Acute Peripheral T-Cell Lymphoma Associated With IgG Plasma Cell Leukemia and IgA Hypergammaglobulinemia. ( 27824644 )
2016
21
Plasma cell leukemia: Single institution experience. ( 28485366 )
2016
22
Plasma cell leukemia mimicking acute myeloid leukemia. ( 28092885 )
2016
23
Progress in the Treatment of Primary Plasma Cell Leukemia. ( 27114588 )
2016
24
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma. ( 26505781 )
2016
25
Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du MyAclome. ( 27114594 )
2016
26
Plasma Cell Leukemia With Prominent Hairy-cell Morphology. ( 27916226 )
2016
27
Multiple myeloma and secondary plasma cell leukemia. ( 27833979 )
2016
28
Plasma cell leukemia revealing a G6PD deficiency. ( 28034875 )
2016
29
Plasma cell leukemia in North India: retrospective analysis of a distinct clinicohematological entity from a tertiary care center and review of literature. ( 27104188 )
2016
30
Primary Plasma Cell Leukemia: Identity Card 2016. ( 26995215 )
2016
31
Hemorrhagic Skin Nodules and Plaques: A Diagnostic Clue to Underlying Primary Plasma Cell Leukemia. ( 27057024 )
2016
32
Abrupt Development of Plasma Cell Leukemia in a Patient with Chronic Anemia under Follow-up. ( 26702753 )
2016
33
Primary plasma cell leukemia 2.0: advances in biology and clinical management. ( 27759436 )
2016
34
Confusing Hairy Cells in a Case of IgG Kappa Plasma Cell Leukemia. ( 27215099 )
2016
35
Plasma Cell Leukemia Presenting as a Chest Wall Mass: A Case Report. ( 27462235 )
2016
36
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia. ( 28038447 )
2016
37
MYEOV gene overexpression in primary plasma cell leukemia with t(11;14)(q13;q32). ( 27446453 )
2016
38
Primary plasma cell leukemia: A report of two cases of a rare and aggressive variant of plasma cell myeloma with the review of literature. ( 27721294 )
2016
39
Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows. ( 26506015 )
2016
40
Radiographic features of plasma cell leukemia in the maxilla: A case report. ( 28035306 )
2016
41
Immunoglobulin D Multiple Myeloma, Plasma Cell Leukemia and Chronic Myelogenous Leukemia in a Single Patient Treated Simultaneously with Lenalidomide, Bortezomib, Dexamethasone and Imatinib. ( 27103978 )
2016
42
Plasma cell leukemia: update on biology and therapy. ( 27819179 )
2016
43
Lower gastrointestinal bleeding in a patient with Crohn's disease and plasma cell leukemia in remission. ( 26289474 )
2015
44
Characterization of a new human plasma cell leukemia cell line UHKT-944. ( 25600340 )
2015
45
Simultaneous occurrence of angioimmunoblastic T-cell lymphoma and plasma cell leukemia. ( 25553298 )
2015
46
Synchronous Thyroid Involvement in Plasma Cell Leukemia Masquerading as Hashimoto's Thyroiditis: Role of Ancillary Cytology Techniques in Diagnostic Workup. ( 26330190 )
2015
47
Plasma cell leukemia mimicking hairy cell leukemia. ( 26013472 )
2015
48
Pleomorphic plasma cell leukemia. ( 26904765 )
2015
49
Colonic plasmacytomas: a rare complication of plasma cell leukemia. ( 25926223 )
2015
50
Atypical plasma cell leukemia mistaken for lymphocytosis on blood count. ( 26756052 )
2015

Variations for Plasma Cell Leukemia

Expression for Plasma Cell Leukemia

Search GEO for disease gene expression data for Plasma Cell Leukemia.

Pathways for Plasma Cell Leukemia

GO Terms for Plasma Cell Leukemia

Biological processes related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 interferon-gamma-mediated signaling pathway GO:0060333 8.62 IRF4 NCAM1

Molecular functions related to Plasma Cell Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 8.62 FGFR3 NCAM1

Sources for Plasma Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....